Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Gefapixant in Renal Insufficiency
NCT03108924Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of gefapixant in chronic cough (4 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero Up to Infinity, Area Under the Concentration-Time Curve From Time Zero to the Last Quantifiable Sample and 3 more. Started Apr 2017; status: completed.
02
Drugs
gefapixant
03
Conditions
chronic cough
Beyond the preview
Go deeper on NCT03108924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03108924.